Please wait...


Generic Name: enasidenib (EN a SID a nib)
Brand Names: IDHIFA
IDHIFA (enasidenib) is used to treat acute myeloid leukemia in adults who have a mutation in the protein that this medicine targets and blocks. Includes Idhifa side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Idhifa

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
IDHIFA (enasidenib) targets a specific gene mutation called IDH2, which can affect your bone marrow. IDH2 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia. IDHIFA is used to treat acute myeloid leukemia in adults with an IDH2 mutation. IDHIFA is used when AML has come back or has not improved with prior treatment. IDHIFA can cause a condition called differentiation syndrome, which affects blood cells and can be fatal if not treated. This condition may occur within 10 days to 5 months after you start taking this medicine. Learn more

Idhifa Side Effects

Idhifa Side Effects

Note: This document contains side effect information about enasidenib. Some of the dosage forms listed on this page may not apply to the brand name Idhifa.

For the Consumer

Applies to enasidenib: oral tablet


Oral route (Tablet)

Patients treated with enasidenib have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

Along with its needed effects, enasidenib (the active ingredient contained in Idhifa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking enasidenib:

More common

  • Agitation
  • blue lips, fingernails, or skin
  • bone pain
  • chest pain
  • chills
  • confusion
  • cough
  • coughing that sometimes produces a pink frothy sputum
  • decreased awareness or responsiveness
  • decreased urine output
  • depression
  • difficult or troubled breathing
  • difficult, fast, noisy breathing
  • dizziness
  • eye pain
  • fainting
  • fast heartbeat
  • fever
  • general feeling of illness
  • headache
  • hostility
  • increased sweating
  • irregular, fast or slow, or shallow breathing
  • irritability
  • lightheadedness
  • loss of consciousness
  • muscle or joint pain
  • muscle twitching
  • nausea
  • pale skin
  • rapid weight gain
  • rapid, shallow breathing
  • seizures
  • severe sleepiness
  • sore throat
  • swelling around the neck, groin, or underarm area
  • swelling of the arms, feet, or lower legs
  • swelling of the face, ankles, or hands
  • unusual drowsiness, dullness, tiredness, weakness or feeling of sluggishness
  • yellow skin or eyes

Some side effects of enasidenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Change in taste
  • decreased appetite
  • diarrhea
  • loss of taste
  • vomiting

For Healthcare Professionals

Applies to enasidenib: oral tablet


The most common (30% or more) adverse reactions of any grade were elevated bilirubin, decreased calcium and potassium levels, nausea, diarrhea, vomiting, and decreased appetite.


Very common (10% or more): Increased total bilirubin (81%)


Very common (10% or more): Decreased calcium (74%), decreased potassium (41%), decreased appetite (34%), decreased phosphorus (27%)

Common (1% to 10%): Tumor lysis syndrome, decreased weight


Very common (10% or more): Nausea (50%), diarrhea (43%), vomiting (34%)

Common (1% to 10%): Abdominal pain


Very common (10% or more): Differentiation syndrome (14%), noninfectious leukocytosis (12%)

Nervous system

Very common (10% or more): Dysgeusia (12%)


Common (1% to 10%): Rash


Common (1% to 10%): Increased uric acid


Common (1% to 10%): Pyrexia, peripheral edema


Common (1% to 10%): Renal insufficiency


Common (1% to 10%): Respiratory failure, dyspnea, hypoxia, pulmonary edema, acute respiratory distress syndrome

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Idhifa